[{"id":"4b7d3f06-90c5-4cd6-8331-cc186109ade1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03391934","created_at":"2021-01-18T16:44:22.837Z","updated_at":"2024-07-02T16:35:51.426Z","phase":"Phase 3","brief_title":"Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer","source_id_and_acronym":"NCT03391934","lead_sponsor":"Cinnagen","biomarkers":" EGFR • RAS","pipe":" | ","alterations":" EGFR expression • RAS wild-type","tags":["EGFR • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • irinotecan • leucovorin calcium • cetuximab biosimilar"],"overall_status":"Recruiting","enrollment":" Enrollment 234","initiation":"Initiation: 01/20/2018","start_date":" 01/20/2018","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2023-04-05"}]